Skip to content
★ Sign in to follow
Anthem Biosciences Limited logo

Anthem Biosciences Limited Stock: price and insider trades · India

IN·Mcap ₹456.6BHealth Care

Anthem Biosciences Limited: what insiders have been doing

Anthem Biosciences Limited is a Health Care company. Its directors and officers file their transactions with SEBI (PIT + SAST). Between 27 October 2025 and 27 October 2026, 5 insiders published 5 filings.

The flow runs one way only: 3 sales worth €124.6M, from 3 insiders, and no purchase. No amount is published for 1 filing, which the totals therefore leave out. Biggest ticket of the year: €117.1M, sold by Viridity Tone LLP and made public on 11 March 2026.

The median gap between a trade and its publication by SEBI (PIT + SAST) is 2 days. This delay matters because a trade only becomes useful information once it is public. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification.

Compared with its exchange (1,893 companies, median 4 filings), a count of 5 filings is above the norm. The full history, which starts in 2026, counts no purchases against 3 sales.

Other companies in the same sector with recent insider buying flagged by our signals: Dynavox Group AB and EssilorLuxottica. These figures are compiled from regulatory filings published by SEBI (PIT + SAST). They describe what insiders did and are not a recommendation.

Insider Decl.
5
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€125M
3 ops. · all time

Who traded when

BuySale
Viridity Tone LLP2 sales
Aruna Ganesh1 sale

This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.

Fundamental score
Ranked 9,649 of 26,912 companies
58.5
score / 100
Value
29
Quality
89
FCF yld1.2%
Earn yld1.1%
EV/EBITDA53.5x
ROE20%
Gross mgn62%
Net mgn28%
Debt/EBITDA0.1x
Pillars2/3

Transparent value + quality ranking, distinct from the insider signal.

Financial data

as of FY 2026

FY ended March 2026 · cache

₹810.25
Analyst consensus
8 analysts
1.38/5
₹850.00Target ₹920.13(+14%)₹1,050.00
Income statement
Revenue₹21.2B
Gross profit₹13.1B62% margin
EBITDA₹9.6B45% margin
Net income₹5.9B28.7% margin
Valuation
PER (trailing)79.8x
PER (forward)53.6x
P/Book15.0x
Balance sheet & cash
Market cap₹456.6B
Total debt₹539.2M
Free Cash Flow₹6.3B
Debt / Equity2%
Profitability & ownership
ROE21.7%
ROA14.2%
% insiders80.9%
% institutions12.8%
Last declaration on 21 September 2026
Declarations5 total
  • ▼
    Related company / holdingExecutives
    827M INR17SEBI
    900,000 shares@ ₹918.600.17% mcap6.0% of flowEquityMarket SaleSEBI:47d82442731a950869c0ff6cf7bf6a6052a5924d
  • ▼
    PromoterExecutives
    0SEBI
    17,114,604 shares-MarketSEBI:dc919f563e3db9771959520d2142d1a209ef97dd
  • ▼
    Related company / holdingExecutives
    13B INR10SEBI
    20,313,795 shares@ ₹617.9286100.0% of flowEquity SharesSEBI:1783566bc7bef1bfa7a4932723a2497ac06ee412
  • ●
    Promoter GroupExecutives
    0SEBI
    8,557,302 sharesEquity SharesSEBI:cd4a3c3149a8daf4aa3705f75ef9fca295f49dbe
  • ●
    Promoter GroupExecutives
    0SEBI
    8,557,302 sharesEquity SharesSEBI:75543cd4c5b69d20e457be577de80ba72372b9e8

5 of 5 declarations

About Anthem Biosciences Limited

Anthem Biosciences Limited is a company in the health and pharmaceutical sector, providing biotechnology and research services. It is listed on the XBOM.

Recent ranked signals in the same sector

Purchases our model currently ranks for the recommendations list.

All recommendations